Mevlyq

Eribulin mesylate, the active ingredient in Mevlyq, is a microtubule dynamics inhibitor presented as an intravenous solution for intravenous use. It is indicated for the treatment of metastatic breast cancer and for unresectable or metastatic liposarcoma in adult patients.

GNH USA supplies Mevlyq as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable logistics for hospital and clinic procurement. Our distribution network covers Europe, Asia, Africa and the Americas, ensuring timely access to essential oncology medicines.

Mevlyq (eribulin mesylate) is used in oncology to target microtubule dynamics in solid tumors.

Metastatic breast cancer: improves overall survival in patients previously treated with anthracycline and taxane therapy. Unresectable or metastatic liposarcoma: provides disease control in adults with advanced soft‑tissue sarcoma.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss during treatment. - Nausea: upset stomach often managed with anti‑emetics. - Peripheral neuropathy: tingling or numbness in extremities. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe infections: opportunistic bacterial or fungal infections. - Pulmonary toxicity: breathing difficulties or interstitial lung disease. - Cardiac dysfunction: reduced heart function or arrhythmias. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances. - Hypersensitivity reactions: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should assess baseline blood counts, liver function, and cardiac status.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess hepatic function: adjust dosing if liver enzymes are elevated. Evaluate peripheral neuropathy: discontinue or modify treatment if severe. Avoid in pregnancy: contraindicated due to potential fetal harm. Use with caution in the elderly: increased susceptibility to toxicity. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Eribulin may interact with several drug classes that affect its safety or efficacy.

Major Interactions (Avoid): - Concomitant use with other microtubule inhibitors: additive toxicity. - Strong CYP3A4 inducers (e.g., rifampin): may reduce eribulin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase eribulin exposure. - Concurrent myelosuppressive agents: heightened risk of severe neutropenia. - QT‑prolonging drugs: potential for cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., tacrolimus): monitor plasma levels. - Anticoagulants (e.g., warfarin): watch for bleeding complications. - Drugs affecting hepatic function: adjust monitoring frequency. - Vaccines (live attenuated): consider timing relative to therapy. - Herbal supplements (e.g., St. John’s wort): may alter metabolism.